C4 Therapeutics, Inc. stock is up 6.71% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 November’s closed higher than October. 67% of analysts rate it a buy.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting multiple myeloma and non-Hodgkin lymphomas. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.